Opportunities for pharmacological intervention in the ras pathway.
The delineation of a ras-dependent signalling pathway from tyrosine kinases to mitogen-activated protein kinases, which is common to a variety of effectors of cell proliferation, suggests that this pathway may provide targets for agents to inhibit cell proliferation. Considerable investigation is needed to determine which points of the pathway are the most suitable for inhibition in terms of effectiveness and selectivity. The use of interfering mutants derived from each component in the pathway is one approach to determining at which point it is best to inhibit.
Marshall
C J
CJ
CRC Centre for Cell and Molecular Biology, Institute of Cancer Research, London, U.K.
D000970:Antineoplastic Agents / Q000494:pharmacology; D017871:Calcium-Calmodulin-Dependent Protein Kinases / Q000037:antagonists & inhibitors; D004791:Enzyme Inhibitors / Q000494:pharmacology; D011905:Genes, ras / Q000187:drug effects*; D006801:Humans; D019950:Mitogen-Activated Protein Kinase 1; D020929:Mitogen-Activated Protein Kinase Kinases; D047428:Protein Kinase Inhibitors; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D015398:Signal Transduction; D014157:Transcription Factors / Q000494:pharmacology
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D047428:Protein Kinase Inhibitors; D014157:Transcription Factors; D011505:Protein-Tyrosine Kinases; D017871:Calcium-Calmodulin-Dependent Protein Kinases; D019950:Mitogen-Activated Protein Kinase 1; D020929:Mitogen-Activated Protein Kinase Kinases